Page 4,893«..1020..4,8924,8934,8944,895..4,9004,910..»

Six PHL hospitals administering non-FDA-approved stem cell therapies, doctors' group claims

Posted: Published on September 24th, 2013

The Philippine College of Physicians urged several hospitals and medical practitioners to adhere to established standards of practice and medical ethics when they perform stem cell therapies (SCT) after they learned that there have been deviations from the three approved uses of stem cells in the country. PCP officials appealed to the Philippines's Food and Drug Administration (FDA) and Professional Regulation Commission on Tuesday to strictly enforce standards of practice involving stem cell cures and probe advertised SCT techniques, adding that the only recognized SCT as of now are: hematopoietic stem cell transplantation; corneal resurfacing with limbal stem cells; and skin regeneration with epidermal stem cells. The PCP said all other SCT done in some hospitals and by some doctors that are not FDA-approved and are off-label, including those purported to address diabetes, autism, and HIV-AIDS must meet rigorous clinical standards and peer review. Hematopoietic stem cell transplantation for specific cancers involves the bone marrow, corneal resurfacing with limbal stem cells concerns the eyes, while skin regeneration with epidermal stem cells is used to treat severe burn cases. Dr. Carlos Lasa, a plastic surgeon, said the cosmetic and aesthetic applications of stem cell techniques have been abused and advised that … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Six PHL hospitals administering non-FDA-approved stem cell therapies, doctors' group claims

Working With Autism Inc. Announces Expansion Into Ventura County for Students With Autism

Posted: Published on September 23rd, 2013

ding Camarillo, Ventura, Oxnard, Thousand Oaks and Bell Canyon) (PRWEB) September 23, 2013 Ventura County, CA (inclu Working With Autism Inc. embarks on business expansion extending from the Antelope Valley to Ventura County for the 2013 school year, providing local Ventura children and teens with quality programming and service. Students in Ventura Countys school system with the diagnosis of autism spectrum disorder will now have access to WWAs early start, school age, and adolescent unit programs run by WWAs Board Certified Behavior Analyst team of Behavior Interventionists. Case Managers local to the Ventura County area will be available to shadow in the schools and provide behavior therapy in families homes after school. The programs offered include highly specialized behavior intervention programs based on empirically supported principles, and include Discrete Trial Training, adaptive skills and social skills programming. Specialized Respite services are also provided by WWA, allowing parents to take some time for themselves while a skilled, CPR and First Aid trained behaviorist cares for their child. Together, Working With Autisms programs offer a highly effective approach to meeting the needs of children with autism from birth to young adulthood. Preschool Children with Autism - 0-3 Years In the Infant Development … Continue reading →

Comments Off on Working With Autism Inc. Announces Expansion Into Ventura County for Students With Autism

Highland Instruments, Inc., Announces New Award of Small Business Innovation Research (“SBIR”) Grant for Clinical …

Posted: Published on September 23rd, 2013

BOSTON--(BUSINESS WIRE)-- Highland Instruments, Inc., (Highland) today announced continuation of award for a multi-year SBIR Grant from the National Institutes of Health National Institute of Neurological Disorders and Stroke (NIH-NINDS) for the clinical evaluation of Highlands ElectroSonic Stimulation (ESStim) technology for the treatment of Parkinsons Disease (PD)1. The main academic partner collaborator in this grant and location of the clinical trial will be Spaulding Rehabilitation (Spaulding) Hospitals Laboratory of Neuromodulation (Boston). Felipe Fregni, MD, PhD, MPH, will be the Lead Clinical Investigator. Dr. Fregni is the Director of the Laboratory of Neuromodulation at Spaulding Rehabilitation Hospital and Associate Professor of PM&R and Neurology at Harvard Medical School. Bill Edelman, Chairman of the Board for Highland, commented, We are thrilled to have received a continuation award of the SBIR Grant for the clinical evaluation of ESStim in PD patients following the successful completion of a Phase 1 study in 24 patients. We also recently completed an initial clinical trial investigating the potential benefits of ESStim for the management of osteoarthritis pain and look forward to further expanding the clinical capabilities of this technology in Parkinsons disease. Dr. Fregni is a pioneer in the field of noninvasive brain stimulation, having conducted groundbreaking … Continue reading →

Comments Off on Highland Instruments, Inc., Announces New Award of Small Business Innovation Research (“SBIR”) Grant for Clinical …

EORH hosting stroke awareness program

Posted: Published on September 23rd, 2013

MARTINS FERRY -- Every four seconds someone in the United States suffers a stroke. Every four minutes someone dies from a stroke in the U.S. Strokes kill more people in the world every year than any other malady. Those medical statistics are quite alarming. With that in mind, two Eastern Ohio Regional Hospital nurses are taking the lead in championing the cause in getting vital stroke information out to the public. Registered nurse Karen Wilkinson and ICU nurse Annette Ganz presented a program at last week's Martins Ferry's monthly Chamber of Commerce luncheon, hosted by the hospital. They outlined "F.A.S.T Times at EORH: A Stroke Awareness Health Fair." It will be held on Wednesday, Oct. 9 from 6:30-8:30 p.m. in the Ruth Brant/RH Wilson Rooms at EORH. It is free to the public. From 6:30-7:30 p.m., those in attendance will be invited to visit tables from the hospital departments as well as a myriad of vendors. East Ohio Regional Hospital has partnered with OhioHealth. It has spawned a much more comprehensive and efficient network in stroke prevention and treatment. OhioHealth includes some of the first hospitals in the state to receive a Primary Stroke Center certification from the Joint Commission. … Continue reading →

Comments Off on EORH hosting stroke awareness program

California Pain Network Doctors in Fresno Now Offering Hope for Chronic Pain with Revolutionary Treatments

Posted: Published on September 23rd, 2013

Fresno, CA (PRWEB) September 23, 2013 The leading California Pain Network pain management doctors in Fresno are now offering revolutionary treatments that are providing hope to those suffering from chronic pain. These treatments include radiofrequency ablation along with spinal cord stimulator implant treatments in addition to the medication management offered. For more information and scheduling, call (559) 201-0399. The Fresno pain management doctors in the California Pain Network are all Board Certified and highly experienced in over 25 options for effective chronic pain treatment. Radiofrequency ablation, for example, is a revolutionary treatment that has been shown to provide pain relief for 12 to 18 months in over 80% of chronic neck and back pain sufferers. For those individuals suffering from failed back surgery syndrome, the Fresno pain clinics can offer spinal cord stimulator implants. This treatment can provide immense back and leg pain relief over 75% of the time. The Fresno pain management clinics treat both simple and complex pain conditions including spinal and extremity arthritis, degenerative disc disease, sciatica, headaches, fibromyalgia, RSD, scoliosis and more. With so many options available, the pain doctors in Fresno are able to customize treatment options and avoid surgery over 90% of the time. … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on California Pain Network Doctors in Fresno Now Offering Hope for Chronic Pain with Revolutionary Treatments

InVivo Therapeutics to Present at 2013 Aegis Healthcare Conference

Posted: Published on September 23rd, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a focus on groundbreaking technologies for thetreatment of spinal cord injuries(SCI) and neurotrauma conditions, today announced that Brian Luque, Director of Investor Relations, is scheduled to present at the 2013 Aegis Healthcare Conference to be held September 25-28, 2013 at The Encore at Wynn Las Vegas. The Companys presentation will be on Thursday, September 26th at 2:00 p.m. PDT. About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments for serious diseases and conditions, including improving function in individuals paralyzed as a result of traumatic spinal cord injury. The Company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the Company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, http://www.invivotherapeutics.com. Safe Harbor Statement Any statements contained in this press release that do not describe historical … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics to Present at 2013 Aegis Healthcare Conference

Linda Ronstadt confronts Parkinson's

Posted: Published on September 23rd, 2013

These days, it's hard for Linda Ronstadt to get around without her forearm crutches. The debilitating effects of Parkinson's disease require her to relax for a few minutes before starting an interview. But once she's ready, the 67-year-old has full command of her voice, even though she's no longer able to sing. Ronstadt's voice was one of music's great treasures, anchoring hits such as When Will I Be Loved and You're No Good and hop-scotching across genres including pop, rock, jazz and folk. She's sold more than 30 million albums. While her singing voice has been silenced, she's expressing herself in her memoir, Simple Dreams. It touches on the many milestones in her career, though more personal matters, like her high-profile romances with Jerry Brown and others, are briefly mentioned or not at all. It also doesn't discuss her Parkinson's diagnosis, which came after the book was written. Ronstadt spoke to The Associated Press about the book and battling the degenerative disease, among other topics. --- Q: HOW HAVE YOU ADAPTED TO LIVING WITH PARKINSON'S? A: I have to ask people to do things for me that are hard. That's been the hardest thing, I think. It's harder to go … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Linda Ronstadt confronts Parkinson's

US court upholds Teva's Azilect patent

Posted: Published on September 23rd, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced that US District Court for the District of New Jersey has ruled in its favor in the Azilect patent infringement case against Mylan Inc. (Nasdaq: MYL). The court has upheld the validity of Tevas patent for the Parkinson's disease treatment, and Teva anticipates the court will enter judgment that prevents Mylan from launching its generic version of Azilect until Tevas patent expires in 2017. Teva sued Mylan in October 2010, and later filed similar patent infringement suits against Watson Pharmaceuticals (now part of Actavis Inc. (NYSE: ACT)), Canada's Apotex Inc., India's Orchid Chemicals & Pharmaceuticals Ltd. (BSE: 524372), and Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ) generics unit Sandoz. Teva settled with Watson, Apotex, and Orchid earlier this year, and Sandoz has agreed that it will be bound by the final ruling in the Mylan case. US Food and Drug Administration (FDA) records show that it has approved in the past few weeks three generic versions of Teva's Azilect. However, the FDA approval only clears one of the hurdles - the regulatory hurdle - en route to market. There is also the legal aspect of patent protection. As is usual … Continue reading →

Posted in Parkinson's Treatment | Comments Off on US court upholds Teva's Azilect patent

EU approval for Multiple Sclerosis drug

Posted: Published on September 23rd, 2013

Three decades of research in Cambridge has been rewarded after the EU agency responsible for regulating new drugs approved a transformational new treatment for multiple sclerosis (MS). In 1975 scientists Cesar Milstein and George Kohler working at the MRC Laboratory of Molecular Biology (LMB) in Cambridge invented the technology for making large quantities of an antibody targeted at one specificity, so-called monoclonal antibodies (work for which they were awarded the Nobel Prize for Physiology or Medicine in 1984). Building on this research, Herman Waldmann, Geoff Hale and Mike Clark from the University of Cambridge, with Greg Winter and Lutz Riechmann in LMB, produced the first monoclonal antibody for potential use as a medicine, Campath-1H (now known as Alemtuzumab), adopting the technique of humanising these antibodies in order to minimise risk of the drug being rejected by patients. Campath-1H was subsequently licensed for the treatment of chronic lymphocytic leukaemia. However, in the 1980s Cambridge clinical scientists also began to explore its use in autoimmune diseases, which occur when the bodys immune system mistakenly attacks healthy tissue. In 1991, Alastair Compston (Professor of Neurology and Head of the Department of Clinical Neurosciences) began to explore the use of Alemtuzumab as a treatment … Continue reading →

Posted in MS Treatment | Comments Off on EU approval for Multiple Sclerosis drug

Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS

Posted: Published on September 23rd, 2013

WESTON, Mass.--(BUSINESSWIRE)-- Biogen Idec (NASDAQ:BIIB - News) will present 58 data sets from the companys multiple sclerosis (MS) clinical portfolio of approved and investigational products at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, October 2-5. The collection of data being presented at ECTRIMS represents Biogen Idecs industry-leading expertise in MS research and showcases the companys deep understanding of differing patient needs. Through decades of cutting-edge science, Biogen Idec has more experience than any other company in advancing the treatment of this disease, recognising that physicians need therapeutic choices to meet treatment goals. Biogen Idec is proud to be at the forefront of innovation in MS, which has been made possible through our research and development efforts over the past 30 years, said Douglas E. Williams, Ph.D., executive vice president, Research and Development at Biogen Idec. Our commitment has enabled us to bring a number of therapy options to patients, and we are excited to be presenting data on some promising candidates which have the potential to broaden the treatment spectrum for people living with this chronic, debilitating disease. Data at ECTRIMS will be presented from across Biogen Idecs portfolio, … Continue reading →

Posted in MS Treatment | Comments Off on Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS

Page 4,893«..1020..4,8924,8934,8944,895..4,9004,910..»